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Prevention of phosphate-induced progression of uremia in rats by 3-
phosphocitric acid. Male Sprague-Dawley rats were rendered uremic by
surgical removal of 70% of functioning renal mass. This produced a
rapid threefold rise in serum creatinine to 0.87 0.067 (saM) mgldl at 2
weeks postoperatively which declined subsequently to a value of 0.64
0.06 (saM) and remained stable thereafter for an additional 4 weeks in
animals maintained on a diet with normal phosphate content. Increase
of dietary phosphate content (02.2% at 2 weeks after surgery produced
a significant and progressive increase in serum creatinine to values
fourfold higher than the mean values in comparable partially nephrecto-
mized control animals maintained on a diet with normal phosphate
content (P < 0.001). This deterioration in renal function was associated
with extensive nephrocalcinosis, tubular dilatation, cellular necrosis,
and marked interstitial inflammation. 3-phosphocitric acid, a compound
which has been shown to prevent calcium phosphate crystal growth as
well as to prevent in vivo nephrocalcinosis, was very effective in
preventing this phosphate-induced deterioration of renal function and in
preventing any significant increase in renal calcium content in animals
fed a high phosphate diet. This compound was also effective in
preventing the renal histologic changes associated with phosphate-
induced uremia.
Prevention de Ia progression de l'urémie induite par des phosphates
chez des rats par de l'acide 3-phosphocitrique. Des rats males Sprague-
Dawley ont été rendus urémiques par l'ablation chirurgicale de 70% de
leur masse fonctionnelle rénale. Cela a entrainé rapidement le triple-
ment de leur créatinine serique a 0,87 0,067 (sEM) mg/dl deux
semaines après l'intervention, qui s'est ensuite abaissée a 0,64 0,06
(saM) et est restée stable pendant quatre semaines chez des animaux
recevant un régime ayant un contenu normal en phosphates. L'augmen-
tation du phosphate alimentaire a 2,2% deux semaines aprés Ia chirurgie
a entraIné une augmentation progressive et significative de Ia créatinine
sérique a des valeurs quatre fois plus fortes que les valeurs moyennes
chez des animaux partiellement néphrectomisés contrôles recevant un
régime contenant une quantité de phosphates normale (P < 0,001).
Cette détérioration de Ia fonction rénale s'associait avec une nephrocal-
cinose étendue, une dilatation tubulaire, une nécrose cellulaire et une
inflammation interstitielle marquee. L'acide 3-phosphocitrique, un
compose qu'est montré capable d'empecher Ia croissance des cristaux
de phosphate de calcium et de prévenir in vivo one nephrocalcinose,
s'est avéré trés efficace pour empêcher une détérioration de Ia fonction
rénale induite par le phosphate, et pour prévenir toute augmentation
significative du contenu calcique renal chez les animaux recevant un
régime riche en phosphore. Ce compose est également capable de
prévenir les modifications histologiques rénales associées avec l'urémie
induite par Ic phosphate.
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MacKay and Oliver [1] published a detailed description of the
pathological changes produced in the rat by the feeding of
excess phosphate. When dietary phosphate content reached
10%, marked cellular necrosis of the most distal portion of the
proximal convolutions occurred, followed by extensive calcifi-
cation in this region. Changes were demonstrable by light
microscopy within 24 hr of beginning such a diet. This change
becomes maximal and irreversible after 15 days of high phos-
phate intake and is associated with a grossly visible change in
the outer stripe of the outer zone of the medulla. Microscopical-
ly, this gross change represents calcium deposits, interstitial
inflammation, tubular collapse, and scarring.
These findings have been confirmed by others [2—41, and
Haut et al have shown that progressively less dietary phosphate
intake is required to produce these changes as renal mass is
reduced [5]. In animals with only one kidney, an increase in
phosphate intake to only twice normal caused marked calcifica-
tion and histological change in the remaining kidney. Most
remarkably, Haut et al reported that extensive calcium deposi-
tion occurred in the kidney despite an apparently normal serum
phosphorus and calcium x phosphorus product. Ibels et al [61
used the remnant-kidney rat model to show that similar histo-
logical change with similar calcium content increase and associ-
ated decrease in glomerular filtration rate occurred with normal
dietary phosphate intake. These changes were prevented in a
comparable group of animals who were maintained on a diet
extremely low in phosphate. Thus, there is strong evidence for
a nephrotoxic effect of phosphate in experimental animals, an
effect that is greatly exaggerated in renal insufficiency.
Though the data are less convincing in humans, there is some
evidence that severe phosphate restriction may reduce the rate
of loss of renal function in patients with very advanced renal
insufficiency [7—91. In general, effective phosphate reduction
requires associated stringent protein restriction (to 15 to 20 g of
dietary protein per day), plus liberal use of phosphate-binding
agents such as aluminum hydroxide [10]. Such a regimen is
neither nutritionally optimum nor readily tolerated by the
majority of patients with endstage renal disease, although it has
been used with success in some such patients.
Because most available evidence indicates that the phos-
phate-induced damage is due largely, if not exclusively, to
calcium phosphate deposition within tissues and is dependent
upon the calcium x phosphorus product and the associated
increased load of phosphate per nephron [11], an agent that
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would inhibit calcium phosphate deposition within the tissues
would possess substantial therapeutic potential. Haut et a! [5]
tried diphosphonates for this purpose with some success, but
the long-term effects of this drug on osseous tissue preclude its
use in humans for any extended length of time.
Tew et al [12] synthesized 3-phosphocitric acid, a compound
thought to be a naturally occurring inhibitor of calcium phos-
phate precipitation [12, 13], and demonstrated that it success-
fully inhibits both precipitation and crystallization in vitro and
in vivo. In the present study we have used this compound to
test its effectiveness in preventing the phosphate-induced renal
damage in the rat remnant kidney model.
Table 1. Quantity of renal tissue removeda
Control
Phosphate
fed
Phospate fed
+
phosphocitrateN=5 N= 12 N=15
Body wt
at surgery
Wt excised
right kidney
Total wt of
excised tissue
left kidney
280 6.1 283 5.8 280 5.1
1.25 0.1 1.28 0.08 1.24 0.05
0.471 0.06 0.432 0.04 0.491 0.02
Methods
Production of remnant kidney model of renal insufficiency.
Thirty-two male Sprague-Dawley rats weighing between 250
and 300 g were subjected to right nephrectomy through a right
flank incision under nembutal-ether anesthesia. Following clo-
sure of the right flank incision, a partial left nephrectomy was
achieved by ligating and removing successively the upper and
lower poles, leaving the middle third intact as the functioning
segment. After removal of the capsule, the right kidney was
weighed, and the weight of the total renal mass was estimated to
be twice the weight of the right kidney [141. The upper and
lower segments of the left kidney were weighed separately, and
weight of the remaining remnant was estimated using the
following formula: 2 (weight right kidney) — weight right kidney
+ total weights of upper and lower thirds of left kidney.
All animals were allowed 2 weeks to recover from surgery,
and then they were randomized into three groups:
(1) Control group (five animals). These animals received a
synthetic diet consisting of 8% fat, 20% protein and 72%
carbohydrate and containing 17.7 mmoles of calcium and 18.8
mmoles of phosphorus plus 1 mg of vitamin A and 200 I.U. of
vitamin D per 100 g of diet [21]. On this regimen the average
daily phosphate intake was calculated as 3.6 mmoles per rat per
day based upon an average food intake of 19 g of food per rat
per day in this control group.
(2) Phosphate-fed group (12 animals). These animals re-
ceived the same diet as the control group, adjusted to contain 71
mmoles of phosphate/100 g diet by addition of dibasic sodium
phosphate. Food intake averaged 16.9 g per rat per day,
providing an estimate of phosphorus intake of 12 mmoles/24 hr.
(3) Phosphocitrate-treated (15 animals). These animals were
treated identically to the phosphate-fed group but also received
50 pmoles of 3-phosphocitric acid given intraperitoneally daily
as the sodium salt. Food intake averaged 19.7 g per day in these
animals, providing a phosphorus intake of 14 mmoles/24 hr.
Each week all animals were weighed and total food and water
intake determined for one 24-hr period. Blood was taken for
creatinine determination before surgery, immediately after sur-
gery and at approximately biweekly intervals after the experi-
ment was begun.
All animals were anesthetized and sacrificed by exsanguina-
tion after 28 days on the specially prepared diet. Following
sacrifice, the kidney remnant was removed, cleaned of fascia
and adipose tissue, weighed, and sectioned transversely; mate-
rial was taken for fixation and staining with hemotoxylin-eosin
and Von Kossa's stain, respectively. Material was also taken
for tissue [Cal determinations. Histologic changes were evalu-
ated and quantified by a pathologist who had no knowledge of
the prior treatment of the animals. The increase in renal mass
was expressed as percentage increase in weight based upon the
estimate of the original weight of the remaining remnant [(final
kidney weight less original weight estimate/original weight
estimate) x 1001. Renal weights and renal [Cal in normal rats
were determined on six normal rats of comparable weight and
age but not operated upon.
Creatinine was measured by a modification of the Bonsnes
and Taussky method [221, calcium by atomic absorption spec-
trometry following extraction by a method developed in this
laboratory [27] and phosphate by a modification of the method
of Fiske and Subbarow [16]. Statistical comparisons between
the groups were based upon the use of Student's nonpaired
test.
Results
The animals in all three groups were similar in weight at the
outset of the experiment (Table 1). The weight of the removed
right kidney was nearly identical in the three groups. The
quantity of renal tissue remaining immediately after nephrecto-
my was estimated at 30 to 33% of the original mass of renal
tissue. The increase in size of the kidney remnant at sacrifice
differed significantly in the three groups (Fig. 1). The phos-
phate-fed group receiving no phosphocitrate exhibited the
greatest increase in mass although these kidneys also showed
the most severe pathologic changes. Renal function was also
poorest in this group as judged by plasma creatinine values. The
contribution of calcium deposits to this increase in weight was
insignificant, representing only 3% of the weight increase. The
percentage increase in mass exhibited by the control group and
the phosphocitrate treated groups was nearly the same; the
mean creatinine value of the phosphocitrate group was slightly
greater than the comparable value for the control group.
Analysis of the creatinine values at sacrifice revealed that
Total wt of
excised tissue
both kidneys 1.73 0.15 1.71 0.10 1.74 0.05
Estimated wt
remaining left
kidney remnant 0.684 0.12 0.843 0.08 0.753 0.04
a All weights are expressed in grams.
3.0
PC 0.00111
p <0.001Fl
P<0.oo1
1-1
P04 Fed
3.6 mmoles P04/day 12 mmoles POday
PC4 Fed + P. Cit
14 mmoles PO/day
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50 pmo/es
estimated as in Table 1 Phosphocitrate/day
Fig. 1. Increase in renal mass associated with increased phosphate
intake. Hatched bars represent the estimated weight of the kidney
remnant at the time of surgery for each of the three groups (mean
sEM). The basis of the estimate is given in the text. Clear bars represent
the weight of the kidney remnant at the time of sacrifice for each group.
The two types of differences are apparent. In addition to the significant
increase in mass exhibited by each group at the time of sacrifice, the
phosphate-fed animals experienced a much more striking increase in
renal mass than did the comparable group which also received phospho-
citrate inaddition to the increased intake of dietary phosphate.
values in the control group and in the group treated with
phosphocitrate were not significantly different, however, the
group fed phosphate without phosphocitrate had creatinine
values that were threefold greater than those of the controls (P
< 0.005). This difference occurred despite the fact that the
treated group actually consumed more phosphate during the
experimental period because of greater food and water intake.
In Figure 2 are shown the creatinine data for the three groups.
The phosphocitrate-treated rats had significantly elevated phos-
phate levels that were not so markedly elevated as in the
animals receiving the high phosphate diet alone, but the differ-
ence was not significant (0.05 <P < 0.10). Also shown in Table
2 are data on serum calcium for the three groups. It is evident
that the calcium x phosphate product was extremely high in
both the phosphocitrate-treated group and the group receiving
increased phosphate alone. Data on sequential plasma creati-
nine determinations are also shown for all three groups in
Figure 2. Despite the greater increase in renal mass seen in the
untreated group, serum creatinine rose faster and reached
higher values in this group, representing a much more severe
deterioration of renal function in the group fed phosphate only.
Figure 3 presents the data on renal calcium content for each
group. The calcium content of the kidneys in the phosphate-fed
animals is nearly eighty-fold greater than values from controls
on a normal diet. In contrast, the phosphocitrate trcated rats
exhibit renal (calcium) values that are on average only twice as
great as the control. Differences between phosphate-fed ani-
mals receiving phosphocitrate and those receiving phosphate
alone were highly significant (P < 0.001).
These functional differences were associated with equally
striking histological differences as shown by representative
sections of renal tissue in Figures 4A and B. The renal paren-
Fig. 2. Sequential crealinine values in (lie three groups. Day zero
represents day of nephrectomy. The animals receiving high phosphate
diet alone were the only ones exhibiting a significant increase in
creatinine value with time during the course of the experiment. Animals
were sacrificed on the 40th day after nephrectomy and the 28th day
after beginning phosphocitrate and/or phosphate. Symbols represent: ,
P < 0.02; P < 0.005; , control-normal P04 intake; ¶ P04 intake:
o P04 + phosphocitrate.
chyma in the animals fed only phosphate showed severe
damage, exhibiting extensive interstitial nephritis, marked tu-
bular dilatation and extensive calcification. In contrast, the
control group and the group treated with phosphocitrate
showed very little distortion of the normal architecture. This
remarkable difference in histological change between the phos-
phate-fed animals receiving phosphocitrate and those receiving
phosphate alone, plus the higher creatinine values in the latter
group, indicate that the much larger increase in mass exhibited
by this group did not result in the achievement of functionally
superior compensatory hypertrophy. It is of further interest that
this group receiving phosphate alone exhibited the least weight
gain during the experimental period. Consequently, if the
increase in renal mass at sacrifice is expressed per unit body
weight and the degree of hypertrophy or mass increase adjusted
to a body weight of 300 g, the observed differences are
somewhat more pronounced (control 65.7%, phosphate-fed
227%, and phosphocitrate-treated 107%).
Discussion
These studies offer conclusive evidence that phosphocitrate
can prevent the renal damage produced by phosphate in the
remnant kidney model of renal insufficiency in the rat. This
protective effect is exerted despite the fact that marked hyper-
phosphatemia persists and the calcium x phosphate product
remains high in animals treated with phosphocitric acid. The
present study was confined to animals receiving intraperitoneal
injections of phosphocitrate. Its efficacy when administered by
other routes remains to be determined.
Both histological and chemical evidence support the view
that the severe renal damage exhibited by the phosphate-fed
1.4
1.2
+
Time, days
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animals in the present experimental series was due to progres-
sive deposition of calcium phosphate in the renal parenchyma
and the associated interstitial nephritis which it produced. The
nephrotoxic effect of increased dietary phosphate intake has
been well established, beginning with the careful work of
MacKay and Oliver [1—6]. Renal damage is related to the
quantity of phosphate ingested as well as the degree of prior
renal damage [5, 6]. Necrosis of cells in the straight portion of
the proximal convoluted tubules is among the earliest changes
seen. This is followed by calcification in the areas of necrosis in
the proximal convoluted tubule. Similar changes have been
seen in the ioop of Henle and elsewhere [1, 2]. Depending upon
the dose and route of administration, calcification of basement
membranes surrounding proximal convoluted tubules in the
outer and inner cortex, glomeruli, and outer medulla are often
associated with calcification of intraluminal casts. Ultrastruc-
tural studies have shown that the earliest lesions can be
identified in the mitochondria of the proximal tubule cells and
consist of swelling, loss of cristae, and distortions of the
internal structure. As in this study, previous reports have
identified increased calcium content associated with these
changes, and it would appear that calcium phosphate precipita-
tion is most likely the initial event leading to progressive renal
damage and loss of function. Hence a plausible explanation for
the mechanism of action of 3-phosphocitric acid in this study is
that it prevented the precipitation and crystallization of calcium
phosphate, thereby preventing progression of renal impairment.
The mechanism whereby 3-phosphocitric acid prevents pro-
gression of renal damage in these animals is related most likely
to its ability to inhibit precipitation and crystallization of
calcium phosphate [12]. Phosphocitrate has been proposed as a
naturally occurring inhibitor of biologic calcification found in
urine and mitochondrial preparations [12, 13, 15]. Although
existence of this substance as a naturally occurring compound
in living tissues has not been unequivocally proven, Tew et al
have synthesized the compound and have shown that it acts as
an extremely powerful inhibitor of calcium phosphate precipita-
tion from metastable solutions as well as an inhibitor of the
accompanying growth of hydroxyapatite crystals [12]. Prelimi-
nary observations have also indicated that the compound is
active in vivo in preventing deposition of calcium phosphate in
tissues under a variety of abnormal situations predisposing to
biologic calcification [17, 18].
P04-Fed + P. Cit
Nephrect.
+
14 mmoles P/d
+
50 pmoles
Phosphocitrate/d
Fig. 3. Renal calcium content (mmolesIlOO g wet wt renal tissue). No
significant difference was observed between cortical and medullary
calcium content in the control animals receiving a normal phosphate
diet after partial nephrectomy. Animals receiving high phosphate intake
only exhibited a marked and highly significant increase in both cortical
and medullary calcium content in the kidney remnant. In contrast, the
animals receiving increased phosphate intake plus phosphocitrate
showed no significant increase in cortical calcium and only a modest
rise in medullary calcium.
The exact mechanism whereby phosphocitrate exerts this
action remains to be clarified, but it has been demonstrated that
phosphocitrate becomes bound to microcrystals of calcium
phosphate thereby preventing crystal growth and facilitating
crystal dissolution in the process of exerting its inhibitory
action [12]. This incorporation into the calcium phosphate
lattice creates a steric hindrance that prevents further crystal
growth. It would appear from the present experiments that it is
sufficiently successful at preventing crystal growth that it
prevents the expected nephrocalcinosis and the attendant inter-
stitial inflammation that produces such marked renal damage.
The demonstration by Ibels et a! [6] that nephrocalcinosis and
interstitial inflammation with progression of renal insufficiency
which occurs in the rat remnant kidney model is prevented by
severe phosphate restriction assumes particular importance in
view of the subsequent observations of Mitch, Gelman, and
Walser and Walser, Mitch, and Collier [8, 9]. They have
accumulated substantial evidence, recently summarized by
Walser [10], that calcium phosphate deposition may play an
important role in determining the rate of deterioration of the
remaining renal function in patients with endstage renal disease.
The observation has been made, by these and other investiga-
tors [8, 9, 25], that extreme reduction in phosphate intake has a
significant moderating effect upon rate of loss of residual renal
Table 2. Data from three groups at sacrifice
Phosphate fed
Phosphate +
Control fed phosphocitrateN=5 N=12 N=15
Remnant kidney wt, g 1.43 0.05 2.43 0.28 1.47 0.08
Kidney hypertrophy, % 86.7% 194.3% 99.5%
Serum creatinine, mgldl 0.61 0.13 1.86 0.23 0.81 0.07
Serum calcium, mg/dl 10.13 0.24 6.02 0.65 7.39 0.41
Serum phosphorus, mgldl 7.41 0.6 16.9 1.9 12.9 1.2
a,
0
S
S
0
a,
0
C.,
E
C.,
C,
Co0
a,
Control
Nephrect.
+
3.6 mmoles P/d
P04- Fed
Nephrect.
+
12 mmoles P/d
a
 
0 
0 
0 
0 
0 
a
 
in renal function has been documented in some individuals on
rigid phosphate restriction l0,25, 261. It thus seems quite likely
that elevation of the serum phosphate level in the presence of
impaired renal function results in an increased calcium x
phosphorus product, and this elevated calcium:phosphate prod-
uct, in the presence of parathormone excess, results in heavy
deposits of calcium phosphate within the kidneys. This meta-
static calcification produces cellular necroses and an inflamma-
tory response which greatly accelerates the rate of renal dam-
age, thereby hastening the appearance of uremia and the need
for maintenance dialysis to support life.
While the studies reported here represent evidence that
phosphocitrate is quite effective in preventing the deposition of
calcium induced in renal tissue by feeding excess phosphates, it
provides no information about the efficacy of this agent in
arresting or preventing the nephrocalcinosis and progressive
maintained on a diet with normal phosphate content. Such
studies are essential before the full potential of phosphocitrate
in preventing phosphate-induced renal damage can be defined.
The present studies nonetheless are of sufficient interest to
warrant examination of its efficacy in protecting the remnant
kidney in animals maintained on normal phosphate intake as
well as its potential for retarding progression of other forms of
experimental renal disease.
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Fig. 4. Photomicrographs of kidneys from animals fed high phosphate diet alone and those receiving high phosphate intake plus phosphocitrate. A
Section of kidney remnant at sacrifice taken from animals receiving high phosphate diet alone (sacrificed after 28 days on increased phosphate
intake). Marked tubular dilatation, extensive calcium deposits within the tubules and Interstices, extensive interstitial inflammation, and scarring
are evident. ft Section of same magnification taken from kidney remnant of rat sacrUlced at same time as animal in A hut receiving both high phos-
phate diet and 50 p.moles of phosphocitrate daily intraperitoneally during the experiment. Renal architecture is much more nearly normal and no
calcification is seen. No interstitial inflammation or scarring is evident in this section. Renal function in this group was correspondingly better as
described in the text.
function in uremic individuals, In fact, temporary improvement loss of renal function seen in the remnant kidney of animals
A z',:-
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